for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cidara Therapeutics Inc

CDTX.OQ

Latest Trade

1.89USD

Change

0.03(+1.61%)

Volume

11,786

Today's Range

1.83

 - 

1.91

52 Week Range

1.24

 - 

4.38

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.86
Open
1.86
Volume
11,786
3M AVG Volume
10.10
Today's High
1.91
Today's Low
1.83
52 Week High
4.38
52 Week Low
1.24
Shares Out (MIL)
26.77
Market Cap (MIL)
50.32
Forward P/E
-1.04
Dividend (Yield %)
--

Latest Developments

More

Mundipharma AG Reports 15.2% Passive Stake In Cidara Therapeutics

Cidara Therapeutics Says Rezafungin Achieved Positive Topline Results In Its Phase 2 Strive B Trial

Cidara Reports Fourth Quarter And Full Year 2018 Financial Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cidara Therapeutics Inc

Cidara Therapeutics Inc., is a clinical-stage biotechnology company focused on developing new anti-infectives. The Company’s lead product candidate is rezafungin acetate, which is a molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, fungal infections associated with high mortality rates. The Company is also leveraging its novel Cloudbreak platform to develop antibody-drug conjugates for the treatment of serious viral and Gram-negative bacterial infections. Cloudbreak is the immunotherapy discovery platform designed specifically to create compounds that directly kill pathogens and also direct a patient’s immune cells to attack and eliminate bacterial, fungal or viral pathogens.

Industry

Biotechnology & Drugs

Contact Info

6310 Nancy Ridge Dr Ste 101

+1.858.7526170

http://www.cidara.com/

Executive Leadership

Jeffrey L. Stein

President, Chief Executive Officer, Principal Financial Officer, Director

James E. Levine

Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer

Paul Daruwala

Chief Operating Officer

Carmen Betancourt

Senior Vice President - Regulatory affairs and quality

Laura A. Navalta

Senior Vice President - Clinical Operations

Key Stats

1.33 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-3.320

2017

-3.180

2018

-2.760

2019(E)

-1.805
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
1.58
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
31.30
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-89.54
Return on Equity (TTM)
-70.63

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up